New CAR T-Cell combo trial targets tough hodgkin lymphoma in youth
NCT ID NCT06617286
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tests whether giving CD30-targeting CAR T-cells after a strong chemotherapy and stem cell transplant is safe and feasible for children, teens, and young adults with poor-risk classical Hodgkin lymphoma. About 21 participants aged 6 to 29 will receive the treatment. The goal is to see if this approach can help those whose cancer has not responded to or has returned after standard treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CD30 CAR T-cells
- What this could lead to
- If successful, this could offer a new treatment option for young people with hard-to-treat Hodgkin lymphoma who have not responded to standard therapies.
- What could go wrong
- This is an early-phase trial with only 21 participants, so results may not apply to everyone. There are risks like cytokine release syndrome and other serious side effects from the CAR T-cells and chemotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSICAL HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
New York Medical College
Valhalla, New York, 10595, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new nucleotide analogue boost cancer treatment?
- Can a drug duo outsmart resistant lymphomas?
- Immunotherapy may let some hodgkin lymphoma patients avoid intensive chemo and radiation
- Two-Drug combo aims to tackle Hard-to-Treat hodgkin lymphoma
- New drug combo aims to tackle Hard-to-Treat hodgkin lymphoma
- Engineered donor cells take on lymphoma in early trial